Multi-center and Multi-modal Deep Learning Study of Gastric Cancer
Multi-center and Multi-modal Deep Learning Study of Diagnosis, Therapeutic Outcome and Prognosis of Gastric Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213001
- The fourth People's Hospital of Changzhou
-
-
Liaoning
-
Chaoyang, Liaoning, China, 122099
- Chaoyang Central Hospital
-
Fushun, Liaoning, China, 113012
- The General Hospital of Fushun Mining Bureau
-
Jinzhou, Liaoning, China, 121012
- First Hospital of Jinzhou Medical University
-
Shenyang, Liaoning, China, 110000
- The First Affiliated Hospital of China Medical University
-
-
Shandong
-
Ji'nan, Shandong, China, 250033
- The Second Hospital of Shandong University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The diagnosis of gastric cancer was confirmed by pathology;
- Preoperative enhanced abdominal CT;
- Available detailed clinical and pathological data;
- Integrated follow-up data.
Exclusion Criteria:
- The patients had severe underlying disease;
- Overall survival was less than 3 months;
- No detailed information could be collected.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Training Group
Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis.
And a model will be constructed based on deep learning.
|
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
HE pathological examination was performed on all specimens of enrolled patients.
|
|
Internal Validation Group
Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
|
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
HE pathological examination was performed on all specimens of enrolled patients.
|
|
External Validation Group
Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
|
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
HE pathological examination was performed on all specimens of enrolled patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum diameter of tumor
Time Frame: 1 day
|
To measure the maximum diameter of tumor on preoperative enhanced abdominal CT of patients with gastric cancer.
|
1 day
|
|
Growth pattern
Time Frame: 1 day
|
To assess the growth pattern on preoperative enhanced abdominal CT of patients with gastric cancer, including endophytic, exophytic and mixed.
|
1 day
|
|
Enhancement pattern
Time Frame: 1 day
|
To assess the enhancement pattern on preoperative enhanced abdominal CT of patients with gastric cancer, including homogeneous and heterogeneous.
|
1 day
|
|
Enhancement degree
Time Frame: 1 day
|
To assess the enhancement degree on preoperative enhanced abdominal CT of patients with gastric cancer, including hypoenhancement, isoenhancement and hyperenhancement.
|
1 day
|
|
Nucleus size
Time Frame: 1 day
|
To obtain the nucleus size of postoperative H&E stained sections and slides of gastric cancer by deep learning.
|
1 day
|
|
Nucleus shape
Time Frame: 1 day
|
To obtain the nucleus shape of postoperative H&E stained sections and slides of gastric cancer by deep learning.
|
1 day
|
|
Distribution of pixel intensity
Time Frame: 1 day
|
To obtain the distribution of pixel intensity of postoperative H&E stained sections and slides of gastric cancer by deep learning.
|
1 day
|
|
Texture of nuclei
Time Frame: 1 day
|
To obtain the texture of nuclei of postoperative H&E stained sections and slides of gastric cancer by deep learning.
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival status
Time Frame: 1 day
|
To analyze the survival status of patients with gastric cancer, involving dead and alive.
|
1 day
|
|
Overall survival
Time Frame: 1 day
|
To calculate the overall survival of patients with gastric cancer based on days to death and days to last follow-up.
|
1 day
|
|
Recurrence/metastasis
Time Frame: 1 day
|
To calculate the days to recurrence/metastasis of patients with gastric cancer.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Kai Li, MD, First Hospital of China Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FirstHCMU_DL_oncology
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.